ArticleBMC infectious diseases2026
Analysis of measles outbreaks reported to Integrated Disease Surveillance Programme (IDSP), India, 2019-2023.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2022, an estimated 1,36,000 measles deaths were reported worldwide, mostly in children under five. In 2022, thirty-seven countries reported extensive or disruptive measles outbreaks by the WHO, while only 22 countries reported similar outbreaks in 2021. According to NFHS-5, 87.9% of children between 12 and 23 months old had received their initial dose of the measles-containing vaccine (MCV), but only 31.9% of children aged 24-35 months who received MCV2. The study aimed to perform descriptive epidemiology of measles outbreaks reported to IDSP in India from 2019 to 2023. METHODOLOGY: We did a secondary data analysis of weekly outbreak data from the Integrated Disease Surveillance Program (IDSP) for the period 2019-2023. We extracted data from publicly available IDSP weekly outbreak reports and analysed them using MS Excel, focusing on time, place, and person distribution.
resultsOut of 259 reported outbreaks, 89% were laboratory-confirmed, and 56.3% of outbreaks were timely, with reporting occurring in the same week. Age distribution was not available in 56% of IDSP outbreak reports. The median (Interquartile range) age was 6.5 (5-9.5). Sex distribution was not available in 96% of IDSP outbreak reports. The 53% (137/259) outbreaks were reported from Bihar (18%), Jharkhand (13%), Uttar Pradesh (11%), and Gujarat (10%). The 25 districts have reported three or more measles outbreaks over five years. These districts account for 117 of the 259 reported outbreaks: Godda (Jharkhand), West Champaran (Bihar), and Nuh (Haryana). The maximum number of outbreaks (116) was recorded in 2023. Vitamin A was given during 56% (114/259) of outbreaks. Twenty deaths were reported.
conclusionsA substantial proportion of outbreaks (72%) were reported from seven states, predominantly in northern and eastern India. The delayed reporting of outbreaks and the absence of age and sex distribution in most reports highlight areas for improvement. Recommendations include timely reporting, inclusion of age and sex data, and ensuring widespread vitamin A supplementation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.